Drugs / Litapiprant
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03663686 Comparator | Oct 2018 → Jan 2019 | asthma | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Litapiprant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03663686 ↗ |
| Action | Inhibit | “inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells” NCT03663686 ↗ |
| Modality | Small molecule | “Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells” NCT03663686 ↗ |
| Route | Oral | “administered orally” NCT03663686 ↗ |